CONCORD, Mass.--(BUSINESS WIRE)--N-of-One, Inc., founded in 2008 as a leader in interpretation of molecular tests in oncology, announced today the launch of RapidInsights for Illumina’s TruSight Tumor 170 (TST170). RapidInsights is a fully automated interpretation solution that, in a matter of minutes, will read the bioinformatics output of the genomic variants produced by the TST170, and return results based on the enormous corpus of medical literature, guidelines, and clinical trials – while also taking into account multi-variant interaction and its impact on appropriate therapies and trials. The ability to provide this interpretation, accurately and quickly, is a cornerstone of understanding cancer.
This solution, like the RapidInsights TST15 launched in 2015, leverages the comprehensive N-of-One somatic database that includes tens of thousands of cases curated and reviewed by N-of-One’s PhD scientists and MD oncologists. RapidInsights TST170, along with other N-of-One solutions, helps to answer the problem that many molecular labs and oncology precision medicine programs have, which is fast and quality interpretation of their molecular tests, in an effort to scale their programs.
“Illumina’s TST170 panel offers an integrated DNA and RNA enrichment-based workflow, targeting cancer-related genetic aberrations, including small variants, gene amplifications, gene fusions, and splice variants. Extracting the insights that this data can provide requires considerable support in expertly synthesizing and annotating the evidence that details the pathogenic or predictive potential for each genetic variant,” said John Leite, PhD, Vice President of Oncology at Illumina. “N-of-One has developed a powerful curated somatic database of evidence and has been a valuable strategic partner to a number of Illumina’s clients to provide interpretation of a wide variety of small and large gene panels.”
“Over the past eight years, N-of-One has invested in a team of oncology and precision medicine experts to analyze thousands of oncology cases with complex genomic data to create case-specific, evidence-based, actionable information. The launch of RapidInsights for Illumina’s TruSight Tumor 170 allows us to leverage that experience to create a fast and cost-effective option for those interested in this panel,” said Chris Cournoyer, CEO, N-of-One. “All of the N-of-One solutions are integrated with genomics platforms, and we are pleased that RapidInsights TST 170 is available immediately through the Philips’ Intellispace Genomics solution – this helps to get it out to Illumina’s clients who need bioinformatics and interpretation right away.”
N-of-One has previously announced a partnership with Philips (AVR) which embeds N-of-One interpretation with Philips' IntelliSpace Genomics solution. Philips' solution also integrates with Illumina's sequencers, giving labs a traceable, end-to-end decision support solution for cancer genomics.
N-of-One is a leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One’s solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. For more information, please visit www.n-of-one.com or call +1 617-202-9808.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.